Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 4
Submit an article Journal homepage
20
Views
1
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evidence-based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis

David A Johnson Digestive and Liver Disease Specialists, 885 Kempsville Road, Suite 114, Norfolk, VA 23502, USA. [email protected]
Pages 371-382 | Published online: 09 Jan 2014

References

  • Dent J, Brun J, Fendrick A eta]. An evidence-based appraisal of reflux disease management — the Genval Workshop Report. Gut44, S1—S16 (1999). Provides comprehensive guidelines for the management of gastroesophageal reflux disease (GERD).
  • Farup C, Kleinman L, Sloan S eta]. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch. Intern. Med. 161,45–52 (2001).
  • Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Night-time heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am. .1. Gastmenterol 98, 1487–1493 (2003).
  • Fendrick AM. Management of patients with symptomatic gastroesophageal reflux disease: a primary care perspective. Am. Gastroenterol 96, S29—S33 (2001).
  • Kahrilas PJ, Falk GW, Johnson DA etal Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment. Pharmacol Ther. 14,1249–1258 (2000).
  • •First clinical trial to show the superiority of a proton pump inhibitor (PM over omeprazole.
  • Richter JE, Kahrilas PJ, Johanson J eta]. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am Gastroenterol 96,656–665 (2001).
  • •Demonstrates the superiority of esomeprazole over omeprazole for the healing of erosive esophagitis.
  • Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility and acid exposure. Am. Gastroenterol 92, S3—S7 (1997).
  • Rai A, Orlando R. Gastroesophageal reflux disease. Cum Opin. Gastroenterol 14, 326–333 (1998).
  • Van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 119, 1439–1446 (2000).
  • Avidan B, Sonnenberg A, Schnell T, Sontag S. Risk factors for reflux esophagitis: a case-control study. Am. Gastroenterol 96,41–46 (2001).
  • Conio M, Filiberti R, Bianchi S etal Risk factors for Barrett's esophagus: a case-control study. Int. j Cancer 97,225–229 (2002).
  • El-Serag H B, Sonnenberg A. Associations between different forms of gastro-oesophageal reflux disease. Gut 41, 594–599 (1997).
  • Csendes A, Smok G, Cerda G, Burdiles P, Mazza D, Csendes P. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis. Esophagus 10, 38–42 (1997).
  • Labenz J Malfertheiner P Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 41,277–280 (1997).
  • Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BE Mec1.1. 326, 737–744 (2003).
  • Sharma P Vakil N. Review article: I-klicobacter pylori and reflux disease. Aliment Phatmacol. Ther 17,297–305 (2003).
  • Orlando R. Reflux esophagitis. In: Textbook of Gastroentemlogy ThInlEdItlon. (Volume 1). Yamada T, Alpers D et al (Eds) . Lippincott Williams & Wilkins, PA, USA, 1235–1263 (1999).
  • Spechler SJ. Epidemiology and natural history of gastro-oesophageal refluxdisease. Digestion 51,24–29 (1992).
  • Spechler SJ, Goyal RK. Barrett's esophagus. N Engl. I Med. 315,362–371 (1986).
  • Dietz J, Meurer L, Maffazzoni DR, Furtado AD, Prolla JC. Intestinal metaplasia in the distal esophagus and correlation with symptoms of gastroesophageal reflux disease. Dis. Esophagus 16,29–32 (2003).
  • Lagergren J, Bergstrom R, Lindgren A, Nyren 0. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl j Med. 340, 825–831 (1999).
  • Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92,549–555 (2001).
  • Haag S, Holtmann G. Reflux disease and Barrett's esophagus. Encloscopy35, 112–117 (2003).
  • Sandler RS, Everhart JE, Donowitz M etal The burden of selected digestive diseases in the United States. Gastroenterology122,1500–1511 (2002).
  • Hollenz M, Stolle M, Labenz J. Prevalence of gastro-oesophageal reflux disease in general practice. Deutsche Meclizinische Wochenschrift 127,1007–1012 (2002).
  • Locke GR III, Talley NJ, Fell SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology112,1448–1456 (1997).
  • McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow-up of its effect on patient symptomatology and quality of life. Gut 38, 481–486 (1996).
  • Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am. j Med 104, 252–258 (1998).
  • Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scantl j Gastroenteml 231(Suppl), 48–54 (1999).
  • Kaplan-Machlis B, Spiegler GE, Revicki DA. Health-related quality of life in primary care patients with gastroesophageal reflux disease. Ann. Pharmacother. 33, 1032–1036 (1999).
  • Kulig M, Leodolter A, Vieth M etal Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease — an analysis based on the ProGERD initiative. Aliment. Pharmacol Ther 18,767–776 (2003).
  • Dimenas E, Carlsson G, Glise H, Israelsson B, Wildund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scantl Gastroenterol 221 (Suppl), 8–13 (1996).
  • Farup C, Kleinman L, Sloan S etal The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch. Intern Merl 161,45–52 (2001).
  • Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wildund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scantl Gastroenterol 28,681–687 (1993).
  • Henke CJ, Levin TR, Henning JM, Potter LP Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am. Gastroenterol 95,788–792 (2000).
  • Bloom BS, Jayadevappa R, Wahl P, Cacciamanni J. Time trends in cost of caring for people with gastroesophageal reflux disease. Am j Gastroenterol 96, S64—S69 (2001).
  • Green J. Is there such an entity as mild oesophagitis? Eur. j Gun. Res. 4,29–34 (1993).
  • Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scantl j Gastroenterol 21, 837–847 (1986).
  • Fennerty B,Traxler B, Hoyle P Heartburn severity does not predict disease severity in gastroesophageal reflux patients with erosive esophagitis. j Gun. Gastroenterol 38(2), 178 (2004).
  • Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroentemlogy126,660–664 (2004).
  • Tefera L, Fein M, Ritter MP etal Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease? Am. Surg. 63,933–936 (1997).
  • Fass R, Ofman JJ, Gralnek IM etal Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch. Intern. Med. 159,2161–2168 (1999).
  • Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24 h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment. Phalmacol. Ther. 14, 389–396 (2000). suppression for the management of gastro-oesophageal reflux disease. Digestion 51, 59–67 (1992).
  • Arango L, Angel A, Molina RI, Marquez JR. Comparison between digestive endoscopy and 24 hour esophageal pH monitoring for the diagnosis of gastroesophageal reflux esophagitis: ‘presentation of 100 cases’. Hepatogastroenterology 47, 174–180 (2000).
  • DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 94, 1434–1442 (1999).
  • ••Provides comprehensive guidelines for the management of GERD.
  • Revicki DA, Crawley JA, Zodet MW, Levine DS, Joelsson BO. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 13, 1621–1630 (1999).
  • Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RII. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 51, 59–67 (1992).
  • Carlsson R, Dent J, Watts R et al Gastro- oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur Gastroenterol Hepatol 10,119–124 (1998).
  • Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Qn.J Gastroenterol 11 (Suppl. B), B66—B73 (1997).
  • Hetzel DJ, Dent J, Reed WD etal Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology95, 903–912 (1988).
  • Netzer P, Brabetz-Hofliger A, Brundler R, Flogerzi B, Husler J, Halter F. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment. Pharmacol Ther. 12, 337–342 (1998).
  • Wyeth JW, Pounder RE, Sercombe JC, Snell CC. The effects of low doses of ranitidine on intragastric acidity in healthy men. Aliment. Pharmacol Ther 12, 255–261 (1998).
  • Shaw MJ, Fendrick AM, Kane RL, Adlis SA, Talley NJ. Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists. Am. .1. Gastroenterol 96, 673–676 (2001).
  • Koppelo KL, Kaplan B. Management of gastroesophageal reflux disease. j Am. Pharm. Assoc. NS36,16–26 (1996).
  • Kahrilas PJ, Fennerty MB, Joelsson B. High-versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am. Gastroenteml 94,92–97 (1999).
  • Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment. Phatmacol Ther. 4\(Suppl. 1), 29–45 (1990).
  • Chiba N, De Gara CJ, Wilkinson JM, Hunt RII. Speed of healing and symptomrelief in Grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology112, 1798–1810 (1997).
  • Holzer SS, Juday TR, Joelsson B, Crawley JA. Determining the cost of gastroesophageal reflux disease: a decision analytic model. Am. j Manag. Cate 4, 1450–1460 (1998).
  • Crawley JA, Madill Schmitt C. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. j Clin. Outcomes Manag. 7, 29–34 (2000).
  • Berardi RR. Proton pump inhibition. An effective, safe approach to GERD management. Postgrad. Med. Spec No, 24–35 (2001).
  • Bell NJ, Hunt RII. Progress with proton pump inhibition. Yalef Biol. Med. 65, 649–692 (1992).
  • Huang JQ, Hunt RII. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. R3t art. Res. Clin Castmenteml 15, 355–370 (2001).
  • Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment. Pharmacol Ther. 13, 49–57 (1999).
  • Mossner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment. Pharmacol Ther. 9, 321–326 (1995).
  • Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment. Phaimacol Ther. 15, 227–231 (2001).
  • Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment. Phaimacol Ther 18, 559–568 (2003).
  • Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Phannacol 77-ier 15, 1729–1736 (2001).
  • •Provides a comprehensive overview of trial results for all PPIs.
  • Korner T, Schutze K, van Leendert RJ etal Comparable efficacy of pantoprazole and omeprazole in patients with moderate-to-severe reflux esophagitis. Results of a multinational study. Digestion 67, 6–13 (2003).
  • Corinaldesi R, Valentini M, Belaiche J, Colin R, Geldof H, Maier C. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment. Pharmacol Ther. 9, 667–671 (1995).
  • Lind T, Rydberg L, Kyleback A etal Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol Ther. 14, 861–867 (2000).
  • Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24 hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci. 47, 954–958 (2002).
  • Miner PB, Katz PO, Chen Y, Sostek MB. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am. Castroenterol 98, 2616–2620 (2003).
  • •First trial to compare the acid suppressive properties of all five PPIs currently available.
  • Röhss K, Wilder-Smith C, Jansson L, Nauclér E. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin. Drug Invest. 24(1), 1–7 (2004).
  • Castell DO, Kahrilas PJ, Richter JE eta]. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am.j Castroenterol 97, 575–583 (2002).
  • •Pivotal trial demonstrating a significant difference in efficacy between two available PPIs.
  • Wahlqvist P, Junghard 0, Higgins A, Green J. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK. PhaimacoEconomics 20, 279–287 (2002).
  • Raghunath AS, Green JR, Edwards SJ. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis. Clin. Ther. 25, 2088–2101 (2003).
  • Johnson DA, Zuckerman S, Levine JG. Impact of age on baseline severity of esophagitis and heartburn and subsequent healing following treatment with esomeprazole or lansoprazole. Castmenterology97, S14 (2002).
  • Johnson DA, Benjamin SB, Vakil NB eta]. Esomeprazole once-daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Aim Castroenterol 96, 27–34 (2001).
  • Vakil N, Shaker R, Johnson DA. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment. Phaimacol Ther. 15, 927–935 (2001).
  • Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive oesophagitis. Drug- Sal 24, 625–635 (2001).
  • Hasselgren B, Claar-Nilsson C, Hasselgren G, Niazi M, Svernhage E. Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole. Clin. avg. Invest. 20,425–431 (2000).
  • Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (5)-isomer of omeprazole. Clin. Pharmacokinet. 40, 523–537 (2001).
  • Rosenberg W, Donald A. Evidence-based medicine: an approach to clinical problem-solving. BE Med. 310, 1122–1126 (1995).
  • •Provides a good overview of the use of evidence-based medicine.
  • Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence-based medicine: what it is and what it isn't. BE Merl 312, 71–72 (1996).
  • Cook DJ, Guyatt GH, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 108, S227—S230 (1995).
  • Davies HT. Interpreting measures of treatment effect. Hosp. Med. 59, 499–501 (1998).
  • Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BE Med. 310, 452–454 (1995).
  • Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. BE Med 312, 426–429 (1996). Excellent description of number needed to treat and discussion of its application in clinical practice.
  • Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl. Merl 318, 1728–1733 (1988).
  • •Describes the number needed to treat.
  • Johnson D, Hoyle P, Traxler B, Levine D. An evidence-based approach provides a quantitative assessment of the efficacy of esomeprazole for healing of erosive esophagitis based on disease severity. Am. j Gastmenterol 98\(Suppl. 1), S16—S44 (2003).
  • Lauritsen K, Devière J, Bigard MA etal Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Arn. Gastmenterol 17,1–9 (2003).
  • Watson DI, Jamieson GG, Baigrie RJ et al Laparoscopic surgery for gastro-oesophageal reflux: beyond the learning curve. Br. Surg. 83,1284–1287 (1996).
  • Spechler SJ, Lee E, Ahnen D et al Long- term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAIVIA 285,2331–2338 (2001).
  • Myrvold HE, Lundell L, Miettinen P etal The cost of long-term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Gut 49,488–494 (2001).
  • Nessen SC, Holcomb J, Tonkinson B, Hetz SP, Schreiber MA. Early laparoscopic nissen fundoplication for recurrent reflux esophagitis: a cost-effective alternative to omeprazole. JSLS3, 103–106 (1999).
  • Johnson DA. Endoscopic therapy for GERD-baking, sewing, or stuffing: an evidence-based perspective. Rev. Gastmenterol Disord 3,142–149 (2003).
  • Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig. Dis. 16,284–291 (1998).
  • Wiklund I, Bardhan KD, Muller-Lissner S etal Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital. J. Gastmenterol Hepatol 30,19–27 (1998).
  • Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56,307–335 (1998).
  • Festen HP, Schenk E, Tan G, Snel P, Nelis Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am j Gastmenteml 94,931–936 (1999).
  • Goves J, Oldring JK, Kerr D etal First-line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment. Phalmacol Ther. 12,147–157 (1998).
  • Levin TR, Schmittdiel JA, Kunz K etal Costs of acid-related disorders to a Health Maintenance Organization. Am. j Merl 103,520–528 (1997).
  • IMS Health, National Prescription Audit PlusTM. Includes retail, mail service and long-term care dispensed RXs. (Data extracted June 2004).
  • Johnson DA, On W Cuccia A, Traxler B, Brown K, Roth T Esomeprazole for the relief of moderate to severe nighttime heartburn and associated sleep disturbance in patients with GERD: a multicenter, randomized, double-blind, placebo-controlled, 4-week study. Gastmenterology126(4 Suppl. 2), 336, (2004).
  • Johnson D, Orr W, Marple C etal Effect of esomeprazole on sleep quality in patients with GERD: patient-reported outcomes from a randomized controlled trial using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. Gastmenterology16(4 Suppl. 2), 601–602, (2004).

Websites

  • National Digestive Diseases Information Clearinghouse. Gastroesophageal reflux disease (Hiatal hernia and heartburn) 2000 www.niddk.nih.gov/health/digest/pubs/ heartbrn/heartbrn.htm (Accessed July 2004)
  • Moore RA, Wiffen P, McQuay HJ, Phillips C. Reflux oesophagitis: quantitative systematic review of the evidence of effectiveness of proton pump inhibitors and histamine antagonists www.jR2.ox.ac.uldbandolier/banopubs/ gordf/gord.html (Accessed July 2004).
  • Nexium® (full prescribing information). Wilmington DE, AstraZeneca LP, USA (2004). www.astrazeneca-us.com (Accessed July 2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.